Unicardia Specjalistyczne Centrum Leczenia Chorob Serca I Naczyn & Unimedica Specjalistyczne Centrum Medyczne & Uniestetica Centrum Chirurgii Plastycznej Rekonstrukcyjnej I Medycyny Estetycznej Malopolskie Kliniki Specjalistyczne Sp. z o.o.
- Address
- Ul. Kluczborska 17/6, 31-271 Krakow, Poland
Cardiovascular Diseases
Research at Unicardia Specjalistyczne Centrum Leczenia Chorob Serca I Naczyn & Unimedica Specjalistyczne Centrum Medyczne & Uniestetica Centrum Chirurgii Plastycznej Rekonstrukcyjnej I Medycyny Estetycznej Malopolskie Kliniki Specjalistyczne Sp. z o.o. focuses strongly on cardiovascular diseases, with studies in acute myocardial infarction, chronic heart failure, heart condition, and broader atherosclerotic cardiovascular disease. These trials are designed to test new treatments, lower major cardiovascular risk, and improve prevention for people at high risk of serious events.
- Evaluating therapies that reduce the risk of heart attack, stroke, and cardiovascular death
- Studying treatment options for heart failure and related hospitalizations
- Improving prevention strategies for people with high-risk ASCVD
The site is also involved in research on lipid-lowering and residual risk management, aiming to help patients reach better long-term cardiovascular outcomes.
Nutritional and Metabolic Diseases
Another major area of research is nutritional and metabolic diseases, especially obesity, overweight, and conditions linked to abnormal cholesterol and cardiometabolic risk. These studies examine whether newer therapies can support weight management, improve lipid control, and reduce the chance of future cardiovascular complications.
- Research in obesity and HFpEF or HFmrEF with obesity
- Trials targeting hypercholesterolemia and elevated LDL-C
- Assessing treatments aimed at lowering cardiometabolic risk and preventing first events
This research reflects a growing focus on the connection between metabolic health and heart disease, with the goal of improving both prevention and treatment effectiveness.
Nervous System Diseases
The site also participates in research within nervous system diseases, including studies in multiple sclerosis. These trials are intended to evaluate new treatment options that may better control disease activity and support people living with relapsing forms of the condition.
- Testing new approaches for multiple sclerosis
- Assessing whether investigational therapies can improve disease control
- Supporting research into more effective long-term management of relapsing neurological disease
Although cardiology is the main department, this broader research activity shows interest in both neurological and cardiometabolic health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Unicardia Specjalistyczne Centrum Leczenia Chorob Serca I Naczyn & Unimedica Specjalistyczne Centrum Medyczne & Uniestetica Centrum Chirurgii Plastycznej Rekonstrukcyjnej I Medycyny Estetycznej Malopolskie Kliniki Specjalistyczne Sp. z o.o.
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2022-04-08 | 2023-09-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.